-
Security Type
-
Preferred Stock
-
Categories
-
Other
-
Min Investment
-
$502
-
Offering Date
-
January 15, 2020
-
Expected Close Date
-
January 09, 2021
-
Target Raise
-
$14.70M
-
Deal Notes
-
$4.40 per share
Company Description
20/20 GeneSystems (“20/20”) is a digital diagnostics company with the core mission of reducing cancer mortality in the U.S. and around the world through early detection.
Key Deal Facts
Huge Market - The global cancer diagnostics market was valued at $7.1 billion in 2015 and is projected to reach $13.1 billion by the year 2020
Experienced Team - Our CEO previously established strategic partnership with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics and Smiths Detection
Traction - We're backed by China’s Ping An Ventures, likely the world’s largest Healthcare AI company (300 million users of its mobile diagnostic app) & thousands of investors
Use of Proceeds
Sales and Marketing, Research and Development, Intellectual Property Development and Protection, Cybersecurity and Patient Privacy Protections, Working Capital and General Corporate
Management Team / Advisory Board Bios
Jonathan Cohen, MS JD.
President & CEO